Background

Melanoma
Treatment with the anti-CTLA-4 checkpoint inhibitor ipilimumab and anti-PD1 nivolumab are associated with durable remissions in patients with solid tumors. We describe the durable remissions associated with these agents. There were 19 patients treated with ipilimumab and 25 patients treated with nivolumab and 1 patient was treated with combination of ipilimumab and nivolumab. In this analysis we included patients with metastatic malignant melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma and Hodgkin's disease.
Methods
The purpose of this analysis is to describe the durable remissions associated with ipilimumab and nivolumab on a variaty of solid tumors treated at a single centre. This is a retrospective data analisys from 45 patients treated either in an expanded access programme, clinical trial setting or post-registration protocol. 
Results
Total of 45 patients
Conclusions
Anti-PD1 and anti-CTLA4 antibody treatment is associated with durable remissions in patients with a variety of solid tumours. Among our patients durable remissions and durable responses were documented in pretreated patients with metastatic malignant melanoma, NSCLC, renal cell carcinoma and Hodgkin's disease. 
Metastatic Malignant Melanoma: Overall Survival
The median survival was 124 days (13-289) 
